Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.
Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days